Accuracy Coverage Pricing Contact
Perrigo Company plc

Perrigo Company plc (PRGO)

Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, incorporated on June 28, 2013, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. The Company manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is also a provider of generic extended topical prescription products. It provides healthcare products across a range of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China.

Consumer Healthcare

The Company's CHC segment is focused on the sale of OTC store brand products, including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food and diagnostic products. The Company markets in various geographies, including the United States, the United Kingdom and Mexico. Its branded products include the Good Sense, Sergeant's, Sentry, Herron, PetArmor value brands, and the ScarAway brand name.

Branded Consumer Healthcare

The Company's BCH segment develops, manufactures, markets and distributes various European OTC brands in categories, such as natural health, cough, cold and allergy, personal care and derma-therapeutics, lifestyle and pain relief. In addition, the segment manages its regulatory, sales and distribution infrastructure to in-license, and sells non-owned brands and generic pharmaceutical products.

Prescription Pharmaceuticals

The Company's Rx segment develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs for the United States and the United Kingdom markets. It offers a range of topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The portfolio also includes select controlled substances, injectables, hormones, women's health products, oral solid dosage forms and oral liquid formulations. Its development areas include other delivery systems, such as oral liquids, metered dose inhalers, injectables and transdermal products. In addition, the Rx segment offers OTC products through the prescription channel (referred to as ORx, these products are marketed using the Perrigo name). ORx products are OTC products that are available for pharmacy fulfillment and healthcare reimbursement when prescribed by a physician. It offers various ORx products that are reimbursable through various health plans and the United States Medicaid and Medicare programs. It manufactures and distributes a range of generic prescription products under various brand names, including Differin, BenzaClin, Entocort, Evoclin, Duac, Olux, Olux-E, Clobex, Desonate, Tridesilon, D.H.E. 45, Ultravate, Bactroban, Mycostatin, Elimite, Klor-Con, Protopic, Androgel, Depo, Testosterone and Triderm/Kenalog.

Specialty Sciences

The Company's Specialty Sciences segment consists of assets focused on the treatment of multiple sclerosis, specifically in connection with the drug, Tysabri (natalizumab). Tysabri also focused on the treatment of Crohn’s diseases.

The Company competes with LNK International, Inc., PL Developments, International Vitamin Corporation, Dr. Reddy's Labs, Johnson & Johnson, Pfizer, Bayer AG, Nestle S.A., Abbott Nutrition, NBTY, Mead Johnson Nutrition Co., Reckitt Benckiser, Boehringer Ingelheim, Novartis, Allergan plc, Apotex Corp., Glenmark Generics Inc., Impax Laboratories, Inc., Mylan N.V., Prasco, LLC, Sandoz, Sun Pharmaceuticals, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, LLC and Zydus Pharmaceuticals, Inc.

Fundamentals

Optimized Dividends

Annual Dividends

Year Amount Change
2006 0.0c
2007 0.0c 0%
2008 0.0c 0%
2009 0.0c 0%
2010 0.0c 0%
2011 0.0c 0%
2012 24.0c 100%
2013 36.0c 50.0%
2014 40.5c 12.5%
2015 48.0c 18.5%
2016 56.0c 16.7%
2017 62.5c 11.6%
2018 73.0c 16.8%
2019 Login required
2020 Login required
2021 Login required

Dividends

Ex-Div Date Pay Date Year Type Frequency Status Amount
01 Mar 2012 unknown 2012 Interim Quarterly Paid 8c
31 May 2012 unknown 2012 Interim Quarterly Paid 8c
30 Aug 2012 unknown 2012 Final Quarterly Paid 8c
28 Nov 2012 unknown 2013 Interim Quarterly Paid 9c
28 Feb 2013 unknown 2013 Interim Quarterly Paid 9c
30 May 2013 unknown 2013 Interim Quarterly Paid 9c
28 Aug 2013 17 Sep 2013 2013 Final Quarterly Paid 9c
26 Nov 2013 17 Dec 2013 2014 Interim Quarterly Paid 9c
19 Dec 2013 unknown 2014 Special Irregularly Paid 1c
26 Feb 2014 18 Mar 2014 2014 Interim Quarterly Paid 10.5c
28 May 2014 17 Jun 2014 2014 Interim Quarterly Paid 10.5c
27 Aug 2014 16 Sep 2014 2014 Final Quarterly Paid 10.5c
25 Nov 2014 16 Dec 2014 2015 Interim Quarterly Paid 10.5c
25 Feb 2015 17 Mar 2015 2015 Interim Quarterly Paid 12.5c
27 May 2015 16 Jun 2015 2015 Interim Quarterly Paid 12.5c
26 Aug 2015 15 Sep 2015 2015 Final Quarterly Paid 12.5c
24 Nov 2015 15 Dec 2015 2016 Interim Quarterly Paid 12.5c
24 Feb 2016 15 Mar 2016 2016 Interim Quarterly Paid 14.5c
25 May 2016 14 Jun 2016 2016 Interim Quarterly Paid 14.5c
24 Aug 2016 13 Sep 2016 2016 Final Quarterly Paid 14.5c
22 Nov 2016 13 Dec 2016 2017 Interim Quarterly Paid 14.5c
01 Mar 2017 21 Mar 2017 2017 Interim Quarterly Paid 16c
24 May 2017 13 Jun 2017 2017 Interim Quarterly Paid 16c
23 Aug 2017 12 Sep 2017 2017 Final Quarterly Paid 16c
30 Nov 2017 19 Dec 2017 2018 Interim Quarterly Paid 16c
01 Mar 2018 20 Mar 2018 2018 Interim Quarterly Paid 19c
31 May 2018 19 Jun 2018 2018 Interim Quarterly Paid 19c
30 Aug 2018 18 Sep 2018 2018 Final Quarterly Paid 19c
29 Nov 2018 18 Dec 2018 2019 Interim Quarterly Paid 19c
28 Feb 2019 19 Mar 2019 2019 Interim Quarterly Paid 19c
30 May 2019 18 Jun 2019 2019 Interim Quarterly Paid 21c
Login Login 2019 Interim Quarterly Declared Login
Login Login 2020 Interim Quarterly Forecast Login
Login Login 2020 Interim Quarterly Forecast Login
Login Login 2020 Interim Quarterly Forecast Login
Login Login 2020 Final Quarterly Forecast Login
Login Login 2021 Interim Quarterly Forecast Login
Login Login 2021 Interim Quarterly Forecast Login
Login Login 2021 Interim Quarterly Forecast Login
Login Login 2021 Final Quarterly Forecast Login

Perrigo Company plc optimized dividend - 12 month history

Optimized dividend graph demo

Perrigo Company plc share price - 12 month history

You're currently viewing outdated and/or artificial data.

Try the real thing now:

Activate Free Trial